Calla Lily wins £700,000 grant for vaginal microbiome platform
Calla Lily Clinical Care secured a £700,000 Innovate UK grant for a £1 million project testing whether Callavid can deliver and retain probiotics in the vaginal microbiome.
By Olivia Hart
5 min read

What's News
- A £700,000 Innovate UK grant supports the £1 million FLORA project co-funded by Innovate UK.
- Research cited by Calla Lily says bacterial vaginosis returns in approximately 58% of women within 12 months.
- The FREEDOM trial evaluates a 400-milligram progesterone formulation and is fully enrolled and nearing completion.
- Three Callavid applications have won competitive external funding: progesterone, antibiotics, and live biotherapeutics and probiotics.
- The FLORA grant is Calla Lily's third Innovate UK award; the company joined Wellcome Leap's $50 million program in 2026.
Calla Lily Clinical Care has won a £700,000 Innovate UK grant toward a £1 million FLORA project to adapt its Callavid intravaginal drug-delivery platform for live biotherapeutic products and probiotics. Innovate UK issued the award through its Growth Catalyst Investor Partnerships program, which combines grant funding with matched private investment. The agency will co-fund the £1 million project.
What does FLORA test?
FLORA stands for Focused Lactobacillus Optimised Retention and Adhesion. Calla Lily Clinical Care said the project will examine how Callavid affects the administration, transfer, retention and colonization of beneficial Lactobacillus species. The company also said Lactobacillus bacteria play an important role in maintaining a healthy vaginal microbiome.
Calla Lily Clinical Care believes Callavid could address leakage, inconsistent dosing and usability challenges in existing probiotic formats. It describes vaginal dysbiosis as an imbalance in the vaginal microbiome commonly associated with bacterial vaginosis. FLORA will focus on that condition.
FLORA must first show that Callavid keeps bacteria in place; the project has not yet shown that it works.
Why is vaginal dysbiosis the target?
Calla Lily cited links between vaginal dysbiosis and increased susceptibility to sexually transmitted infections, including human papillomavirus and HIV. The company also cited associations with pelvic inflammatory disease, miscarriage, preterm birth, reduced fertility and poorer outcomes from in vitro fertilization.
Calla Lily said treatment for common dysbiosis-related conditions remains largely based on antibiotics, and those conditions can recur after treatment. The company cited research indicating that bacterial vaginosis returns in approximately 58% of women within 12 months.
Calla Lily also said repeated antibiotic treatment may contribute to the broader public-health challenge of antimicrobial resistance. It believes delivering beneficial Lactobacillus directly to the relevant location could restore the vaginal microbiome and potentially reduce the need for repeated antibiotic courses.
Thang Vo-Ta, Co-Founder and Chief Executive Officer of Calla Lily Clinical Care, said: “innovate UK has backed us from our earliest days and helped us build Callavid capital-efficiently. This third award takes us into an entirely new area.
In under two years, the Callavid platform has won competitive funding for three different therapies: progesterone, antibiotics, and now live biotherapeutics and probiotics.
The vaginal microbiome is one of the most exciting frontiers in women’s health, but even the best bacteria will only help if they reach the right place and stay there.
This is where Callavid can make a real difference for women.”
The commercial promise depends on better retention and fewer repeat antibiotic courses; neither outcome is established.
How will Calla Lily measure colonization?
Calla Lily plans to develop a proprietary laboratory model alongside the device adaptation. The company said the model will help it evaluate bacterial colonization, including how effectively different bacteria transfer and remain in place. It added that data from the system could guide future vaginal microbiome products.
Calla Lily aims to develop Callavid as an over-the-counter product designed to maximize probiotic transfer, retention and colonization. The company said FLORA remains in development and effectiveness for this indication requires laboratory work and any required clinical and regulatory processes.
Dr. Annalisa Jenkins, Advisor to Calla Lily Clinical Care, Former Chief Executive Officer of Dimension Therapeutics, and Chair of Ori Biotech, said: “Over my career I have seen promising medicines fall short not because the science was wrong, but because getting them to the right place in the body proved harder than anyone expected.
The vaginal microbiome is a clear example. The science behind live biotherapeutics is moving quickly, yet how they are delivered has had far less attention.
If we can help women restore and maintain a healthy microbiome, we may improve her quality of life and reduce how often she will need repeated courses of antibiotics, lowering the potential for resistance that affects us all.
Calla Lily has already taken Callavid from concept into the clinic, and this award gives the team the chance to tackle that delivery problem head on.”
Calla Lily must measure colonization next; clinical effectiveness and over-the-counter access come later.
What has Callavid already achieved?
FLORA expands Callavid beyond its initial applications involving progesterone and antibiotics. Calla Lily Clinical Care said the platform optimizes delivery of therapies administered intravaginally.
The National Institute for Health and Care Research has funded development involving progesterone for threatened miscarriage. Wellcome Leap is supporting targeted antibiotic delivery intended to spare the gut microbiome. The Innovate UK award adds live biotherapeutics and probiotics for vaginal microbiome health.
Calla Lily also said the FLORA grant is its third Innovate UK award. The company is conducting the FREEDOM trial, funded by the National Institute for Health and Care Research, to evaluate a 400-milligram progesterone formulation delivered through Callavid in patients diagnosed with luteal phase insufficiency.
Calla Lily said luteal phase insufficiency raises the risk of infertility and miscarriage. The company added that the FREEDOM trial has enrolled every planned participant and is approaching completion.
Calla Lily joined Wellcome Leap’s $50 million Focused Antibiotics program in 2026. The company said the initiative seeks to change antibiotic delivery while addressing antimicrobial resistance objectives.
The three funded applications mark Calla Lily’s attempt to establish Callavid as a platform rather than a delivery system for a single therapeutic product. Calla Lily Clinical Care is a clinical-stage women’s health company focused on improving delivery for reproductive and vaginal health conditions.
Callavid now has three funded applications, but FLORA still needs measurable microbiome performance before a clinical or over-the-counter product is ready.
Source: pulse2.com
More from Olivia Hart
Show full bio
Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.
2,232 articles